NOVEL IMMUNOTHERAPIES IN LYMPHOMA
With
Dr Sean Harrop
Clinical Haematology Fellow
Peter MacCallum Cancer Centre,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | May 2025
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
He has research interests in novel immunotherapies in lymphoma, mechanisms that lead to immunotherapy resistance and the genetic mechanisms underlying the tumour microenvironment.
He has published in peer-reviewed journals, co-authored textbook chapters and presented at international conferences on clinical and translational research in lymphoma.
Dr Harrop’s upcoming PhD is funded by the Leukaemia Foundation, Haematology Society of Australia and New Zealand (HSANZ) and the Peter MacCallum Cancer Centre.
Source: Supplied and adapted
You Might also like
-
Big data to improve the use of antidepressant medicines in aged care
Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).
Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
-
Impact of NextSense Institute Research in the field of sensory disabilities
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.